McKelligon Brian's Form 4 filing
Akoya Biosciences, Inc. (AKYA) · filed Jun 6, 2023
- Accession no.
- 0001104659-23-068652
- Filed
- Jun 6, 2023, 9:45 PM ET
- Trade date
- Jun 6, 2023
- Filing delay
- Same day
- Rule 10b5-1 plan
- Checked
This filing lists 2 non-derivative transactions and 1 derivative transaction. Open-market sales total $28.5K. It was filed on the trade date.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| McKelligon BrianCIK 0001857447 | Director, Officer (President/CEO) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Jun 6, 2023 | Common Stock | MOption exerciseAcquired | +5,000 | $0.303 | +$1,515 | 157,563 | Direct | |
| Jun 6, 2023 | Common Stock | SSaleDisposed | −5,000 | $5.71 | −$28,537 | 152,563 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Jun 6, 2023 | Common Stock | MOption exerciseDisposed | −5,000 | $0.00 | $0 | 328,129 | Direct |
Footnotes
Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.